Phase I Clinical Trial of Dose Escalated Bortezomib + ATO (Arsenic Trioxide) + Melphalan as a Conditioning Regimen for Multiple Myeloma.

Trial Profile

Phase I Clinical Trial of Dose Escalated Bortezomib + ATO (Arsenic Trioxide) + Melphalan as a Conditioning Regimen for Multiple Myeloma.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Bortezomib (Primary) ; Arsenic trioxide; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Oct 2009 Planned end date (1 Jun 2014) added as reported by ClinicalTrials.gov.
    • 19 Dec 2007 Status change from recruiting to suspended.
    • 08 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top